ES2429941T3 - Candesartán cilexetilo micronizado estable y métodos para preparar el mismo - Google Patents

Candesartán cilexetilo micronizado estable y métodos para preparar el mismo Download PDF

Info

Publication number
ES2429941T3
ES2429941T3 ES10156812T ES10156812T ES2429941T3 ES 2429941 T3 ES2429941 T3 ES 2429941T3 ES 10156812 T ES10156812 T ES 10156812T ES 10156812 T ES10156812 T ES 10156812T ES 2429941 T3 ES2429941 T3 ES 2429941T3
Authority
ES
Spain
Prior art keywords
candesartan cilexetil
candesartan
cilexetil
particle size
fine particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10156812T
Other languages
English (en)
Spanish (es)
Inventor
Ziv Kurgan
Michael Pesachovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2429941(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2429941T3 publication Critical patent/ES2429941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES10156812T 2005-05-10 2006-05-10 Candesartán cilexetilo micronizado estable y métodos para preparar el mismo Expired - Lifetime ES2429941T3 (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US67995205P 2005-05-10 2005-05-10
US679952P 2005-05-10
US68011505P 2005-05-11 2005-05-11
US680115P 2005-05-11
US68445505P 2005-05-24 2005-05-24
US684455P 2005-05-24
US70741705P 2005-08-10 2005-08-10
US707417P 2005-08-10
US70995405P 2005-08-19 2005-08-19
US709954P 2005-08-19
US71699505P 2005-09-13 2005-09-13
US716995P 2005-09-13
US72238805P 2005-09-29 2005-09-29
US722388P 2005-09-29

Publications (1)

Publication Number Publication Date
ES2429941T3 true ES2429941T3 (es) 2013-11-18

Family

ID=37101528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10156812T Expired - Lifetime ES2429941T3 (es) 2005-05-10 2006-05-10 Candesartán cilexetilo micronizado estable y métodos para preparar el mismo

Country Status (10)

Country Link
US (1) US20070082055A1 (enExample)
EP (2) EP1763525A2 (enExample)
JP (2) JP2008505935A (enExample)
KR (1) KR100978592B1 (enExample)
CA (1) CA2599415C (enExample)
DE (1) DE202006020979U1 (enExample)
ES (1) ES2429941T3 (enExample)
IL (1) IL185106A0 (enExample)
TW (1) TW200716615A (enExample)
WO (1) WO2006122254A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505935A (ja) * 2005-05-10 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド 超微粉砕された安定性カンデサルタンシレキセチル及びその調製方法
JP5595820B2 (ja) * 2010-01-15 2014-09-24 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
US8399501B2 (en) * 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法
JP6231553B2 (ja) 2012-05-07 2017-11-15 バイエル ファーマ アクチエンゲゼルシャフト ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法
EP2952187A4 (en) 2013-01-30 2016-08-17 Sawai Seiyaku Kk PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW284688B (enExample) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
DE69517832T2 (de) * 1994-01-28 2000-11-09 Takeda Chemical Industries, Ltd. Ein Verfahren zur Herstellung von Tetrazolyl-Verbindungen
JP2730501B2 (ja) 1994-01-28 1998-03-25 武田薬品工業株式会社 テトラゾリル化合物の製造法
JP3003030B2 (ja) * 1997-05-26 2000-01-24 武田薬品工業株式会社 アミノベンゼン化合物の製造法
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
CN1204125C (zh) * 2000-12-27 2005-06-01 中国科学院上海药物研究所 坎地沙坦酯的合成新路线
EP1420016A4 (en) * 2001-08-03 2006-11-15 Takeda Pharmaceutical CRYSTAL AND METHOD FOR MANUFACTURING THE SAME
CN1953973A (zh) * 2004-05-05 2007-04-25 特瓦制药工业有限公司 高纯度坎地沙坦酯的制备
WO2005123720A1 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
US20060165806A1 (en) 2005-01-06 2006-07-27 Elan Pharma International Limited Nanoparticulate candesartan formulations
JP2008505935A (ja) * 2005-05-10 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド 超微粉砕された安定性カンデサルタンシレキセチル及びその調製方法

Also Published As

Publication number Publication date
TW200716615A (en) 2007-05-01
IL185106A0 (en) 2007-12-03
EP2210888A2 (en) 2010-07-28
WO2006122254A3 (en) 2007-01-25
EP1763525A2 (en) 2007-03-21
JP2008505935A (ja) 2008-02-28
EP2210888A3 (en) 2010-09-15
EP2210888B1 (en) 2013-04-24
US20070082055A1 (en) 2007-04-12
CA2599415C (en) 2011-07-19
WO2006122254A2 (en) 2006-11-16
JP2010270148A (ja) 2010-12-02
CA2599415A1 (en) 2006-11-16
KR20070062500A (ko) 2007-06-15
KR100978592B1 (ko) 2010-08-27
DE202006020979U1 (de) 2011-08-05

Similar Documents

Publication Publication Date Title
ES2699951T3 (es) Formas cristalinas de 5-(2,6-di-4-morfolinil-4-pirimidinil)-4-trifluorometilpiridin-2-amina, un inhibidor PIK3
JP2017128605A (ja) 抗ウイルス化合物の固体形態
ES2467676T3 (es) Polvo de un compuesto orgánico combinado para uso médico, método para producir el mismo y suspensión del mismo
CN106573934B (zh) 瞬时受体电位a1离子通道的抑制
BR122021005510B1 (pt) Forma ii do cristal de 2-{4-[n-(5,6-difenilpirazin-2-il)-n isopropilamino]butilóxi}-n- metilsulfonil)acetamida e composição farmacêutica
JP2010270148A (ja) 超微粉砕された安定性カンデサルタンシレキセチル及びその調製方法
JP2002502873A (ja) 化合物
KR20170043561A (ko) 셀리넥소의 다형태
US20100121072A1 (en) Candesartan cilexetil polymorphs
CN104284897B (zh) 替卡格雷晶型及其制备方法和用途
CN102958926A (zh) 作为抗组胺剂的卢帕他定盐
CN101663314B (zh) D-异谷氨酰基-d-色氨酸的一钠盐的晶态形式
ES2463681T3 (es) Formas cristalinas de 3-[5-cloro-4-[(2,4-difluorobencil)oxi]-6-oxopirimidin-1 (6H)-il]-N-(2-hidroxietil)-4-metilbenzamida
JP2007527924A (ja) 非晶質バルサルタンの製造方法
CN105418614A (zh) 替格瑞洛的新结晶形式及其制备方法和用途
ES2845639T3 (es) Forma cristalina de 6-[(4R)-4-metil-1,2-dióxido-1,2,6-tiadiazinan-2-il]isoquinolin-1-carbonitrilo
CN109721557A (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
JP6270603B2 (ja) ブリモニジン酒石酸塩の新規多形及びその製造方法
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
MX2007000523A (en) Stable micronized candesartan cilexetil and methods for preparing thereof
JP2005330277A (ja) カンデサルタンシレキセチル多形体
US20090304797A1 (en) Process for the Preparation of Micronized Valsartan
CN121985944A (zh) 7H－吡咯并［2,3－d］嘧啶－4－胺衍生物的晶体